Klaus Hellerbrand

This inventor holds 10 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 7 EPO patents. Top assignees: Scil Technology Gmbh, Boehringer Mannheim Gmbh. Active years: 2001-2018.

USPTO Granted Patents = 10 (Patent Applications = 3)

% Patents Active = 20.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 7 (Patent Applications = 1)

Average Co-Inventor Count = 3.2

ph-index = 3

Forward Citations = 73(Granted Patents)

Location History:

Geltendorf, DE (2001 - 2013)
Moorenweis, DE (2013 - 2018)

Company Filing History:

Boehringer Mannheim Gmbh

patents

Years Active: 2001-2018

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9907829 - Stable MIA/CD-RAP formulation (2018-03-06),

2. 9526761 - Dried reconstituted vesicle formation for pharmaceutical application (2016-12-27),

3. 9511116 - Stable MIA/CD-RAP formulation (2016-12-06),

4. 8829072 - Biomaterial containing degradation stabilized polymer (2014-09-09),

5. 8546334 - Device having osteoinductive and osteoconductive properties (2013-10-01),

6. 8372895 - Biomaterial containing degradation stabilized polymer (2013-02-12),

7. 8372419 - Coated implants, their manufacturing and use thereof (2013-02-12),

8. 8257728 - Metal implant coated under reduced oxygen concentration with osteoinductive protein (2012-09-04),

9. 7763270 - Metal implant coated under reduced oxygen concentration with osteoinductive protein (2010-07-27),

10. 6238664 - Process for stabilizing proteins (2001-05-29),

Title: Klaus Hellerbrand: Innovator in Pharmaceutical Formulations

Introduction

Klaus Hellerbrand is a notable inventor based in Moorenweis, Germany. He has made significant contributions to the field of pharmaceutical formulations, holding a total of 10 patents. His work focuses on developing stable formulations that can be used in therapeutic applications, particularly for inflammatory disorders.

Latest Patents

One of Hellerbrand's latest patents is for a stable MIA/CD-RAP formulation. This invention relates to stable aqueous formulations comprising at least 5 mg/mL CD-RAP and a charged amino acid. The formulation is designed to maintain stability over repeated freeze-thaw cycles and is intended for use in therapy, specifically for treating inflammatory disorders such as osteoarthritis. Another significant patent involves dried reconstituted vesicle (DRV) compositions. This invention includes water-based formulations that contain therapeutic agents, particularly hydrophilic proteins. The DRVs are designed to form large multilamellar liposomes that encapsulate active agents in an aqueous phase upon reconstitution.

Career Highlights

Throughout his career, Klaus Hellerbrand has worked with several prominent companies in the pharmaceutical industry. Notably, he has been associated with Scil Technology GmbH and Boehringer Mannheim GmbH. His experience in these organizations has contributed to his expertise in developing innovative pharmaceutical solutions.

Collaborations

Hellerbrand has collaborated with various professionals in his field, including notable coworkers such as Michael Siedler and Andreas Schuetz. These collaborations have likely enhanced his research and development efforts, leading to successful innovations.

Conclusion

Klaus Hellerbrand's contributions to pharmaceutical formulations demonstrate his commitment to advancing medical science. His innovative patents and collaborations reflect his expertise and dedication to improving therapeutic options for patients.